We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.4B
AUM Growth
+$48.4M
Cap. Flow
+$23.3M
Cap. Flow %
1.66%
Top 10 Hldgs %
65.74%
Holding
68
New
19
Increased
7
Reduced
4
Closed
19
Avg Time Held Equity + Options
2.4 quarters
Top 10 Avg Time Held Equity + Options
2.4 quarters
Top 20 Avg Time Held Equity + Options
2.9 quarters
Avg Time Held Equity only
2.6 quarters
Top 10 Avg Time Held Equity only
2.4 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$122M
2
NRIX icon
Nurix Therapeutics
NRIX
+$30M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$14M
5
KLRS icon
Kalaris Therapeutics
KLRS
+$13.3M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$69.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$40.6M
3
FATE icon
Fate Therapeutics
FATE
+$21.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.5M
5
DNLI icon
Denali Therapeutics
DNLI
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Miscellaneous 4.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNCR icon
1
Xencor
XNCR
$1.75B
$176M 12.58%
4,547,072
– –
2018 Q4
7 quarters
KURA icon
2
Kura Oncology
KURA
$874M
$141M 10.07%
4,608,529
– –
2015 Q4
19 quarters
RLAY icon
3
Relay Therapeutics
RLAY
$3.8B
$136M 9.72%
+3,200,649
New +$122M
2020 Q3
0 quarters
PRTA icon
4
Prothena Corp
PRTA
$429M
$94.2M 6.71%
9,426,640
– –
2018 Q4
7 quarters
MORF icon
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$77.6M 5.54%
2,839,884
+1,911
+0.1% +$50.1K
2019 Q2
5 quarters
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$77.1M 5.5%
464,298
+106,449
+30% +$14.6M
2018 Q4
7 quarters
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.17B
$66.1M 4.71%
2,642,218
– –
2020 Q2
1 quarter
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$59.2M 4.22%
2,103,950
– –
2020 Q2
1 quarter
ANAB icon
9
AnaptysBio
ANAB
$1.36B
$47.5M 3.39%
3,223,324
+148,310
+5% +$2.68M
2019 Q4
3 quarters
NGNE icon
10
Neurogene
NGNE
$431M
$46.4M 3.31%
193,147
+16,313
+9% +$3.95M
2018 Q2
9 quarters
AKUS
11
DELISTED
Akouos Inc
AKUS
$45.2M 3.22%
1,975,984
– –
2020 Q2
1 quarter
ASMB icon
12
Assembly Biosciences
ASMB
$414M
$41.9M 2.99%
212,365
-50,451
-19% -$12.7M
2019 Q3
4 quarters
NRIX icon
13
Nurix Therapeutics
NRIX
$2.3B
$41.6M 2.97%
+1,192,156
New +$30M
2020 Q3
0 quarters
AMTI
14
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$36.6M 2.61%
1,150,000
– –
2020 Q2
1 quarter
BCEL
15
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$33.9M 2.42%
2,426,685
+937,500
+63% +$14M
2019 Q2
5 quarters
GERN icon
16
Geron
GERN
$771M
$33.5M 2.39%
19,230,769
– –
2020 Q2
1 quarter
STRO icon
17
Sutro Biopharma
STRO
$183M
$31.3M 2.23%
311,362
+128,513
+70% +$12.1M
2020 Q2
1 quarter
RCUS icon
18
Arcus Biosciences
RCUS
$2.87B
$31M 2.21%
1,810,000
– –
2018 Q1
10 quarters
SURF
19
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$23M 1.64%
3,333,177
-1,700,684
-34% -$10.3M
2018 Q2
9 quarters
KRSA
20
Korsana Biosciences, Inc. Common Stock
KRSA
$1.44B
$16.7M 1.19%
19,588
– –
2019 Q2
5 quarters
KLRS icon
21
Kalaris Therapeutics
KLRS
$53.1M
$12.3M 0.88%
+19,435
New +$13.3M
2020 Q3
0 quarters
CBIO icon
22
Crescent Biopharma
CBIO
$480M
$11.4M 0.82%
37,252
+18,362
+97% +$7.02M
2020 Q2
1 quarter
TNGX icon
23
Tango Therapeutics
TNGX
$3.75B
$8.29M 0.59%
+800,000
New +$8.17M
2020 Q3
0 quarters
CNST
24
CALL
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.1M 0.58%
400,000
– –
2020 Q2
1 quarter
VINC icon
25
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$7.82M 0.56%
+31,525
New +$6.41M
2020 Q3
0 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2020 Portfolio in Review

As of Q3 2020, EcoR1 Capital held 68 positions worth $1.4B, up 3.6% from $1.35B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

EcoR1 Capital's Q3 2020 filing shows 19 new, 7 increased, 4 reduced and 19 closed positions. Its largest new stake was Relay Therapeutics: 3,200,649 shares worth $136M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $69.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2020 buy was Relay Therapeutics: 3,200,649 shares worth $136M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2020, an estimated $14.6M increase.
  • EcoR1 Capital's biggest Q3 2020 reduction was Assembly Biosciences, cutting an estimated $12.7M.
  • EcoR1 Capital fully exited Dicerna Pharmaceuticals, Inc. in Q3 2020, selling an estimated $69.1M.
  • EcoR1 Capital's ten largest holdings make up 66% of its $1.4B portfolio in Q3 2020.
  • EcoR1 Capital opened 19 new positions and closed 19 in Q3 2020.
  • EcoR1 Capital's portfolio value rose 3.6% quarter-over-quarter to $1.4B.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.